Breaking News

Takeda to Acquire LigoCyte

October 5, 2012

Expands vaccine portfolio

Takeda America Holdings, Inc., a subsidiary of Takeda Pharmaceutical Co., will acquire LigoCyte Pharmaceuticals for an upfront payment of $60 million, with future payments based on the progress of development projects. LigoCyte is a privately held biopharma company specializing in vaccine products, and is headquartered in Bozeman, MT. Its lead vaccine product to prevent norovirus gastroenteritis is in Phase I/II development. LigoCyte has also initiated preclinical development of vaccines against respiratory syncytial virus, influenza and rotavirus.
“Takeda’s acquisition of LigoCyte is a major step forward in the expansion of Takeda’s vaccine business, and a demonstration of Takeda’s dedication to preventing illness in children and adults around the world,” said Rajeev Venkayya, M.D., executive vice president of Takeda’s Vaccine Business Division (VBD), which was launched in January 2012. “Norovirus is the most common cause of outbreaks of gastroenteritis and foodborne illness in the U.S., and is responsible for 200,000 deaths each year, most of them in developing countries. With the only norovirus vaccine in clinical trials today, Takeda will be in a position to change this picture.”
Takeda will continue operating LigoCyte in Bozeman and plans to retain the management team and its employees. Mr. Beeman and his management team will become a part of Takeda’s Vaccine Business Division.
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials